Stayble Therapeutic’s rights issue oversubscribed
The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 percent by existing shareholders and the public. Guarantee commitments made in connection with the rights issue will therefore not be utilized. Stayble will thus receive approximately SEK 41.5 million before transaction related costs. The capital that Stayble is now provided is intended to finance the Company's operations until completion and processing of the results from the Company's ongoing clinical Phase